MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Journal Article

Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells

2017
Request Book From Autostore and Choose the Collection Method
Overview
The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non‐CSCs was set up to study their interaction with non‐MHC‐restricted γδ T cells and antigen‐specific CD8+ T cells. Stable lines with characteristics of breast CSC‐like cells were generated from ras‐transformed human mammary epithelial (HMLER) cells as confirmed by their CD44hi CD24lo GD2+ phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non‐adherent conditions, as well as their potent tumorigenicity, self‐renewal and differentiation in xenografted mice. The resistance of CSC‐like cells to γδ T cells could be overcome by inhibition of farnesyl pyrophosphate synthase (FPPS) through pretreatment with zoledronate or with FPPS‐targeting short hairpin RNA. γδ T cells induced upregulation of MHC class I and CD54/ICAM‐1 on CSC‐like cells and thereby increased the susceptibility to antigen‐specific killing by CD8+ T cells. Alternatively, γδ T‐cell responses could be specifically directed against CSC‐like cells using the humanised anti‐GD2 monoclonal antibody hu14.18K322A. Our findings identify a powerful synergism between MHC‐restricted and non‐MHC‐restricted T cells in the eradication of cancer cells including breast CSCs. Our research suggests that novel immunotherapies may benefit from a two‐pronged approach combining γδ T‐cell and CD8+ T‐cell targeting strategies that triggers effective innate‐like and tumour‐specific adaptive responses.